Format

Send to

Choose Destination
Clin Med Insights Oncol. 2018 Jun 4;12:1179554918779587. doi: 10.1177/1179554918779587. eCollection 2018.

Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review.

Author information

1
Division of General Internal Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
2
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Florida, Gainesville, FL, USA.
3
Division of Hematology & Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
4
Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, FL, USA.

Abstract

Objective:

Bevacizumab is approved for use in combination with chemotherapy for metastatic/recurrent cervical cancer (CC), with increased survival/response rates. However, use of bevacizumab is not always feasible or safe. The purpose of this study was to identify the percentage of metastatic/recurrent CC patients at our institution who would have been eligible to receive bevacizumab.

Methods:

A retrospective study was conducted to identify metastatic/recurrent CC patients treated at UFHealth between 2006 and 2016. Chart review was performed to determine if the patient met bevacizumab eligibility criteria.

Results:

In total, 79 patients with metastatic/recurrent CC were identified; 85.5% would have been ineligible to receive bevacizumab, and 14.5% would have been eligible. The most common reason for exclusion was active bleeding (68.4%); 94% of which was vaginal. In all, 27.6% would be excluded due to poor renal function, and 23.7% due to poor performance status (PS).

Conclusions:

Despite improved survival, only 14.5% of metastatic/recurrent CC patients treated over a 10-year period would have been eligible to receive bevacizumab. Most patients would have been excluded due to active bleeding, most commonly vaginal bleeding, a common complication from their disease. Identifying novel therapies for metastatic/recurrent CC patients with improved safety profiles that would allow for their use in this challenging population is critical.

KEYWORDS:

Bevacizumab; bleeding; eligibility; metastatic cervical cancer; recurrent cervical cancer; retrospective review

Conflict of interest statement

Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center